92 related articles for article (PubMed ID: 24251545)
1. Discovery of novel anti-HIV-1 agents based on a broadly neutralizing antibody against the envelope gp120 V3 loop: a computational study.
Andrianov AM; Kashyn IA; Tuzikov AV
J Biomol Struct Dyn; 2014 Dec; 32(12):1993-2004. PubMed ID: 24251545
[TBL] [Abstract][Full Text] [Related]
2. Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01.
Andrianov AM; Kashyn IA; Tuzikov AV
J Mol Graph Model; 2015 Sep; 61():262-71. PubMed ID: 26298811
[TBL] [Abstract][Full Text] [Related]
3. In silico design of novel broad anti-HIV-1 agents based on glycosphingolipid β-galactosylceramide, a high-affinity receptor for the envelope gp120 V3 loop.
Andrianov AM; Kornoushenko YV; Kashyn IA; Kisel MA; Tuzikov AV
J Biomol Struct Dyn; 2015; 33(5):1051-66. PubMed ID: 24942968
[TBL] [Abstract][Full Text] [Related]
4. Immunophilins and HIV-1 V3 loop for structure-based anti-AIDS drug design.
Andrianov AM
J Biomol Struct Dyn; 2009 Feb; 26(4):445-54. PubMed ID: 19108583
[TBL] [Abstract][Full Text] [Related]
5. Computational model of the HIV-1 subtype A V3 loop: study on the conformational mobility for structure-based anti-AIDS drug design.
Andrianov AM; Anishchenko IV
J Biomol Struct Dyn; 2009 Oct; 27(2):179-93. PubMed ID: 19583444
[TBL] [Abstract][Full Text] [Related]
6. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization.
Rosen O; Chill J; Sharon M; Kessler N; Mester B; Zolla-Pazner S; Anglister J
Biochemistry; 2005 May; 44(19):7250-8. PubMed ID: 15882063
[TBL] [Abstract][Full Text] [Related]
7. Potential HIV-1 fusion inhibitors mimicking gp41-specific broadly neutralizing antibody 10E8: In silico discovery and prediction of antiviral potency.
Andrianov AM; Kashyn IA; Tuzikov AV
J Bioinform Comput Biol; 2018 Apr; 16(2):1840007. PubMed ID: 29439644
[TBL] [Abstract][Full Text] [Related]
8. Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs.
Stanfield R; Cabezas E; Satterthwait A; Stura E; Profy A; Wilson I
Structure; 1999 Feb; 7(2):131-42. PubMed ID: 10368281
[TBL] [Abstract][Full Text] [Related]
9. Computational anti-AIDS drug design based on the analysis of the specific interactions between immunophilins and the HIV-1 gp120 V3 loop. Application to the FK506-binding protein.
Andrianov AM
J Biomol Struct Dyn; 2008 Aug; 26(1):49-56. PubMed ID: 18533725
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel promising targets for anti-AIDS drug developments by computer modeling: application to the HIV-1 gp120 V3 loop.
Andrianov AM; Anishchenko IV; Tuzikov AV
J Chem Inf Model; 2011 Oct; 51(10):2760-7. PubMed ID: 21888425
[TBL] [Abstract][Full Text] [Related]
11. Structural analysis of the envelope gp120 V3 loop for some HIV-1 variants circulating in the countries of Eastern Europe.
Andrianov AM; Kornoushenko YV; Anishchenko IV; Eremin VF; Tuzikov AV
J Biomol Struct Dyn; 2013; 31(7):665-83. PubMed ID: 22888999
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D.
Mester B; Manor R; Mor A; Arshava B; Rosen O; Ding FX; Naider F; Anglister J
Biochemistry; 2009 Aug; 48(33):7867-77. PubMed ID: 19552398
[TBL] [Abstract][Full Text] [Related]
13. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
14. Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp120.
Neurath AR; Strick N; Debnath AK
J Mol Recognit; 1995; 8(6):345-57. PubMed ID: 9052975
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site.
Ghiara JB; Ferguson DC; Satterthwait AC; Dyson HJ; Wilson IA
J Mol Biol; 1997 Feb; 266(1):31-9. PubMed ID: 9054968
[TBL] [Abstract][Full Text] [Related]
16. Structural analysis of the HIV-1 gp120 V3 loop: application to the HIV-Haiti isolates.
Andrianov AM; Veresov VG
J Biomol Struct Dyn; 2007 Jun; 24(6):597-608. PubMed ID: 17508782
[TBL] [Abstract][Full Text] [Related]
17. Structural dynamics of V3 loop with different electrostatics: implications on co-receptor recognition: a molecular dynamics study of HIV gp120.
Chandramouli B; Chillemi G; Giombini E; Capobianchi MR; Rozera G; Desideri A
J Biomol Struct Dyn; 2013 Apr; 31(4):403-13. PubMed ID: 22876913
[TBL] [Abstract][Full Text] [Related]
18. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC
J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346
[TBL] [Abstract][Full Text] [Related]
19. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy.
Zvi A; Feigelson DJ; Hayek Y; Anglister J
Biochemistry; 1997 Jul; 36(28):8619-27. PubMed ID: 9214308
[TBL] [Abstract][Full Text] [Related]
20. Computational study of HIV gp120 as a target for polyanionic entry inhibitors: Exploiting the V3 loop region.
Hollingsworth LR; Brown AM; Gandour RD; Bevan DR
PLoS One; 2018; 13(1):e0190658. PubMed ID: 29346393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
